Update on the use of Trandolapril in the management of cardiovascular disorders

Clicks: 284
ID: 14197
2008
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Star

Ranked #10 of 36 articles by views in Vascular health and risk management

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Ariel Diaz1, Anique Ducharme21University of Montreal, Trois-Rivieres; 2Department of Medicine, Montreal Heart Institute Research Center, Montreal, Quebec, CanadaAbstract: Trandolapril is a well known angiotensin converting enzyme (ACE) inhibitor with many cardiovascular (CV) indications. The objectives of this article are to review the pharmacokinetics and pharmacodynamics properties of trandolapril and to focus on its clinical relevance in cardiovascular medicine. Various populations have been studied in large clinical trials including patients with congestive heart failure (CHF) after an acute myocardial infarction (AMI), diabetics, patients with hypertension (HTN), stable coronary artery disease (CAD) and prevention of proteinuria. Long-term treatment with trandolapril in patients with reduced left ventricular function soon after AMI significantly reduced the risk of overall mortality, mortality from CV causes, sudden death, and the development of severe CHF. Treatment with trandolapril after AMI complicated by left ventricular dysfunction appears to be of considerable importance in patients with diabetes mellitus by saving lives and substantially reducing the risk of progression to severe CHF as well. Moreover, trandolapril reduces progression to proteinuria in high-risk patients. Some of the advantages of trandolapril over other ACE inhibitors are the wide spectrum of patient populations studied, the well established dosage and its proven trough-to-peak effect ratios permitting a safe once-a-day administration.Keywords: trandolapril, angiotensin converting enzyme inhibitors, hypertension cardiovascular diseases, diabetic nephropathy
Reference Key
diaz2008updatevascular Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Diaz, Ariel;Ducharme, Anique;
Journal Vascular health and risk management
Year 2008
DOI
DOI not found
URL
https://www.dovepress.com/update-on-the-use-of-trandolapril-in-the-management-of-cardiovascular--peer-reviewed-article-VHRM
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.